Aclaris Therapeutics, Inc. (ACRS)
4.07
+1.45
(+55.34%)
USD |
NASDAQ |
Jan 20, 13:26
Aclaris Therapeutics Shareholders Equity (Quarterly): 120.10M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 631.90M |
| Puma Biotechnology, Inc. | 115.27M |
| Nephros, Inc. | 10.01M |
| Prelude Therapeutics, Inc. | 58.53M |
| Vivos Therapeutics, Inc. | 2.532M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 175.53M |
| Total Liabilities (Quarterly) | 55.43M |
| Debt to Equity Ratio | 0.0187 |
| Current Ratio | 3.925 |
| Net Debt Paydown Yield | 0.06% |